Literature DB >> 11981263

Hyperlipidemia in kidney disease: causes and consequences.

Meena Sahadevan1, Bertram L Kasiske.   

Abstract

Dyslipidemias are common in patients with chronic kidney disease. The causes vary with the stage of kidney disease, the degree of proteinuria, and the modality of end-stage renal disease treatment. Dyslipidemias have been associated with kidney disease progression, and a number of small, randomized, controlled trials of lipid-lowering agents have been conducted. Unfortunately, the results of these trials, although encouraging, have been inconclusive because of the small numbers of patients enrolled. Dyslipidemias may also contribute to the high incidence of cardiovascular disease in patients with chronic kidney disease. This is most likely for patients with chronic renal insufficiency and for kidney transplant recipients. Less certain is the role of dyslipidemias in the pathogenesis of cardiovascular disease among dialysis patients.

Entities:  

Mesh:

Year:  2002        PMID: 11981263     DOI: 10.1097/00041552-200205000-00009

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  2 in total

1.  Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G.

Authors:  Rangnath Mishra; Michael S Simonson
Journal:  Cardiovasc Diabetol       Date:  2005-01-10       Impact factor: 9.951

2.  Edible Bird's Nest Regulates Hepatic Cholesterol Metabolism through Transcriptional Regulation of Cholesterol Related Genes.

Authors:  Zhang Yida; Hussah Al-Shuwayah; Maznah Ismail; Mustapha Umar Imam
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-09       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.